Skip to main content

Don’t invest unless you’re prepared to lose all your money.
These are high-risk investments and you are unlikely to be protected if something goes wrong.
Take 2 mins to learn more.

Sector
Consumer Wellness
Region
London UK
Stage
Commercialisation
Fund Life Sciences EIS
Target Raise
£200k

Cloud-based platform accessing circa 25 wellness therapies (depending on location), such as acupuncture, massage, yoga, relationship counselling in a patient’s local area.

The Investment Opportunity

Keia was founded to enable patients to easily locate wellness practitioners in their local area. The Company’s cloud-based platform provides access to wellness therapies, ranging from acupuncture, massage and physiotherapy to relationship counselling and yoga. In addition, the wider wellness market also encompasses beauticians, hairdressers and masseurs and these professions will also be included in the Company’s innovative digital platform. 

The platform aims to bring these varied services to the consumer via home visits, video appointments, and clinic visits. A significant selling point for the platform is that it allows the practitioners to build their own personalised ‘shop front’ and profile to attract custom. 

The global fitness and wellness markets are highly competitive, with the Global Wellness Institute estimating a global market size of $4.2tn. However, the Company has reported that there is currently no single, potentially global platform that brings together all available wellness offerings into one single consumer view. 

The Company has stated that its ultimate objective is to become the primary go-to source for consumers seeking wellness information and opinion, offering a benefit to both the needs of the consumer and the practitioner. It intends to become the trusted global brand through which consumers can research, compare and book.

Keia Wellness Limited Website
Milestones to Date
2018

Deepbridge initially invested £150k via Deepbridge Life Sciences SEIS.

2019

Prototype undergone initial tests at Alder Hey Children’s Hospital.

Formed a user panel of early adopters including Salford Royal NHS Foundation Trust, The Pennine Acute Hospitals and Birmingham Children’s Hospital Charity.

2020

Article written by the CEO and published in The Lancet Infectious Diseases, an international medical journal.

Risks and Important Information

This page is a financial promotion for the purposes of Section 21 of the Financial Services and Markets Act 2000. The content of the page has been approved by Deepbridge Capital LLP. The Company may not gain the commercial traction that is forecast, it could experience development problems and may not be able to achieve its objectives. Please note that these risks are by no means exhaustive and there may be other risks which could have a material adverse impact on the Company’s financial performance. The content should not be construed as financial advice. Any decision to invest should be made only on the basis of the relevant documentation for each investment. Past performance is not necessarily a guide to future performance. The value of an investment may go down as well as up and investors could lose the total value of their investment. Investments in small unquoted companies carry a high- level of risk. These investments are highly illiquid and as such, there may not be a readily available market to sell such an investment. Tax treatment depends on the individual circumstances of each investor and may be subject to change in future. The availability of tax reliefs depends on the Company invested in maintaining its qualifying status. Deepbridge does not provide specific individual advice on the suitability of investments with regard to a potential investor’s individual circumstances, risk tolerance or investment objectives and investors should seek independent financial advice if they are in any doubt whether a product is suitable for them.